Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Halozyme Therapeutics enters the final stretch before its November 3 earnings with a notable reversal in the short-selling picture: after weeks of shorts quietly retreating, the position has rebuilt sharply this week, even as analysts are lifting targets and options traders remain firmly on the call side.
The shift in short interest is the clearest change from last week's note. Short interest has climbed 7.5% over the past week to 12.9% of the free float, reversing the gradual decline that had been the dominant trend through September and into early October. That puts the position back above where it sat for most of last month. The borrow market, however, tells a different story from what the directional move might imply. Borrowing costs remain low at 0.52%, barely changed on the week, and availability is generous at 334%, meaning there are more than three shares available for every one currently lent out. Shorts rebuilding here face no friction and no squeeze pressure. The ORTEX short score has nudged up to 64.5 from 62.7 a week ago, consistent with the uptick in shares short, but still well within the range it has held for several weeks.
Options positioning has not followed the shorts' lead. The put/call ratio is 0.46, sitting roughly half a standard deviation below its 20-day average of 1.02, meaning the options market is skewed toward calls rather than hedges. That divergence is the central tension in the setup: short sellers are adding exposure while options traders remain positioned for upside. The put/call ratio has been broadly stable around 0.46 for the past week, unchanged from where the previous note left it, suggesting options participants are unmoved by the short interest rebuild.
Analyst activity reinforces the bullish side of that split. TD Cowen raised its target to $130 from $105 on October 13, the most recent move and a significant step up. JP Morgan also lifted its target on October 8, to $78 from $70, though it kept a Neutral rating, a useful reminder that the Street is not uniformly enthusiastic. HC Wainwright moved its target to $130 from $115 on the same day. The mean price target across the analyst universe is $104.89, which sits a few dollars below the current price of $109.62, a modest discount that reflects the Neutral and equal-weight voices pulling the average down. Earnings momentum is a clear positive: the 12-month forward EPS growth estimate ranks in the 93rd percentile of the ORTEX universe, and analyst recommendation direction ranks in the 92nd percentile, two of the stronger factor scores in the snapshot. The bull case centres on accelerating royalty revenue from ENHANZE partnerships, with Q2 royalty revenue of roughly $307.7M beating estimates and management raising full-year guidance. The bear case points to clinical, regulatory, and competitive risks inherent in a platform that depends heavily on partners' own drug programmes.
The CEO activity from last week is worth noting for context. Helen Torley exercised options and sold roughly $4.1M in shares across October 7 and 8, all under a pre-arranged 10b5-1 plan. The planned nature of those trades matters: they reflect a scheduled programme rather than a discretionary judgment on near-term direction.
Halozyme's last earnings print was striking. The August 6 result produced a 23% single-day move and held a 20% gain through the following week, the clearest data point on how the market treats a beat from this company. The November 3 print arrives in 20 days, and the question the current setup poses is whether the short interest rebuild reflects genuine scepticism about a repeat or simply tactical positioning in a liquid name heading into a high-conviction event.
See the live data behind this article on ORTEX.
Open HALO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
